14 results on '"Antonazzo, Ippazio C"'
Search Results
2. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
- Author
-
Ponticelli, Domenico, Madotto, Fabiana, Conti, Sara, Antonazzo, Ippazio C., Vitale, Andrea, Della Ragione, Giovanni, Romano, Maria L., Borrelli, Mario, Schiavone, Beniamino, Polosa, Riccardo, Ferrara, Pietro, and Mantovani, Lorenzo G.
- Published
- 2022
- Full Text
- View/download PDF
3. Epidemiology of SLE in Italy: an observational study using a primary care database
- Author
-
Ferrara, P, Antonazzo, I, Zamparini, M, Fornari, C, Borrelli, C, Boarino, S, Bettiol, A, Mattioli, I, Palladino, P, Zanzottera Ferrari, E, Emmi, G, Mantovani, L, Mazzaglia, G, Ferrara, Pietro, Antonazzo, Ippazio C, Zamparini, Manuel, Fornari, Carla, Borrelli, Cristiana, Boarino, Silvia, Bettiol, Alessandra, Mattioli, Irene, Palladino, Pasquale, Zanzottera Ferrari, Elena, Emmi, Giacomo, Mantovani, Lorenzo G, Mazzaglia, Giampiero, Ferrara, P, Antonazzo, I, Zamparini, M, Fornari, C, Borrelli, C, Boarino, S, Bettiol, A, Mattioli, I, Palladino, P, Zanzottera Ferrari, E, Emmi, G, Mantovani, L, Mazzaglia, G, Ferrara, Pietro, Antonazzo, Ippazio C, Zamparini, Manuel, Fornari, Carla, Borrelli, Cristiana, Boarino, Silvia, Bettiol, Alessandra, Mattioli, Irene, Palladino, Pasquale, Zanzottera Ferrari, Elena, Emmi, Giacomo, Mantovani, Lorenzo G, and Mazzaglia, Giampiero
- Abstract
Objectives: To estimate the incidence and prevalence of SLE in Italy, and to describe the demographic and clinical characteristics of patients with newly diagnosed SLE. Methods: A retrospective cohort study was conducted using The Health Improvement Network general practice database in Italy, encompassing data from 634 753 people. SLE cases were identified over the period 2017-2022, employing three alternative definitions to provide a more detailed understanding of SLE characteristics. Incidence rates were expressed as cases per 100 000 person-years and prevalence as cases per 100 000 people. Demographic and clinical characteristics of incident SLE cases were also studied. Results: From 2017 to 2022, a total of 191 incident and 1385 prevalent cases were identified under our first definition. In 2022, the incidence rate was 6.51 cases (95% CI 6.29 to 6.74) per 100 000 person-years, and the prevalence 60.57 (95% CI 59.89 to 61.25) per 100 000 people, being the prevalence five times higher in women compared with men. Both estimates have trended upwards since 2017. A geographical variation across the country was also seen. The demographic and clinical characteristics of incident SLE cases were described, while the potential associations of SLE incidence with some pre-existing conditions were observed, such as chronic kidney disease, chronic hepatic disease, rheumatoid arthritis and Sjogren's syndrome. Conclusions: The results of this nationwide study, the first conducted in Italy, showed that the incidence of SLE has increased in Italy in recent years. Age, sex, and area of residence strongly correlate with the epidemiology of this condition.
- Published
- 2024
4. Time-Trends in Air Pollution Impact on Health in Italy, 1990-2019: An Analysis From the Global Burden of Disease Study 2019.
- Author
-
Conti, Sara, Fornari, Carla, Ferrara, Pietro, Antonazzo, Ippazio C., Madotto, Fabiana, Traini, Eugenio, Levi, Miriam, Cernigliaro, Achille, Armocida, Benedetta, Bragazzi, Nicola L., Cadum, Ennio, Carugno, Michele, Crotti, Giacomo, Deandrea, Silvia, Cortesi, Paolo A., Guido, Davide, Iavicoli, Ivo, Iavicoli, Sergio, La Vecchia, Carlo, and Lauriola, Paolo
- Subjects
GLOBAL burden of disease ,AIR pollution ,PARTICULATE matter ,EPISTEMIC uncertainty ,AIR quality - Abstract
Objectives: We explored temporal variations In disease burden of ambient particulate matter 2.5 pm or less in diameter (PM
2.5 ) and ozone in Italy using estimates from the Global Burden of Disease Study 2019. Methods: We compared temporal changes and percent variations (95% Uncertainty Intervals [95% UI]) in rates of disability adjusted life years (DALYs), years of life lost, years lived with disability and mortality from 1990 to 2019, and variations in pollutant-attributable burden with those in the overall burden of each PM2.5 - and ozone-related disease. Results: In 2019, 467,000 DALYs (95% UI: 371,000, 570,000) were attributable to PM2.5 and 39,600 (95% UI: 18,300, 61,500) to ozone. The crude DALY rate attributable to PM2.5 decreased by 47.9% (95% UI: 10.3, 65.4) from 1990 to 2019. For ozone, it declined by 37.0% (95% UI: 28.9, 44.5) during 1990-2010, but it increased by 44.8% (95% UI: 35.5, 56.3) during 2010-2019. Age-standardized rates declined more than crude ones. Conclusion: In Italy, the burden of ambient PM2.5 (but not of ozone) significantly decreased, even in concurrence with population ageing. Results suggest a positive impact of air quality regulations, fostering further regulatory efforts. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
5. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply
- Author
-
Ferrara, Pietro, Antonazzo, Ippazio C., and Polosa, Riccardo
- Published
- 2022
- Full Text
- View/download PDF
6. Time-Trends in Air Pollution Impact on Health in Italy, 1990–2019: An Analysis From the Global Burden of Disease Study 2019
- Author
-
Conti, Sara, primary, Fornari, Carla, additional, Ferrara, Pietro, additional, Antonazzo, Ippazio C., additional, Madotto, Fabiana, additional, Traini, Eugenio, additional, Levi, Miriam, additional, Cernigliaro, Achille, additional, Armocida, Benedetta, additional, Bragazzi, Nicola L., additional, Cadum, Ennio, additional, Carugno, Michele, additional, Crotti, Giacomo, additional, Deandrea, Silvia, additional, Cortesi, Paolo A., additional, Guido, Davide, additional, Iavicoli, Ivo, additional, Iavicoli, Sergio, additional, La Vecchia, Carlo, additional, Lauriola, Paolo, additional, Michelozzi, Paola, additional, Scondotto, Salvatore, additional, Stafoggia, Massimo, additional, Violante, Francesco S., additional, Abbafati, Cristiana, additional, Albano, Luciana, additional, Barone-Adesi, Francesco, additional, Biondi, Antonio, additional, Bosetti, Cristina, additional, Buonsenso, Danilo, additional, Carreras, Giulia, additional, Castelpietra, Giulio, additional, Catapano, Alberico, additional, Cattaruzza, Maria S., additional, Corso, Barbara, additional, Damiani, Giovanni, additional, Esposito, Francesco, additional, Gallus, Silvano, additional, Golinelli, Davide, additional, Hay, Simon I., additional, Isola, Gaetano, additional, Ledda, Caterina, additional, Mondello, Stefania, additional, Pedersini, Paolo, additional, Pensato, Umberto, additional, Perico, Norberto, additional, Remuzzi, Giuseppe, additional, Sanmarchi, Francesco, additional, Santoro, Rocco, additional, Simonetti, Biagio, additional, Unim, Brigid, additional, Vacante, Marco, additional, Veroux, Massimiliano, additional, Villafañe, Jorge H., additional, Monasta, Lorenzo, additional, and Mantovani, Lorenzo G., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Editorial: Overcoming boundaries in public health: Advances in international and global health
- Author
-
Antonazzo, Ippazio C., primary, Sultana, Janet, additional, and Ferrara, Pietro, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up-Reply
- Author
-
Ferrara, Pietro, Antonazzo, Ippazio C., Polosa, Riccardo, Ferrara, P, Antonazzo, I, and Polosa, R
- Subjects
COVID-19 Vaccines ,SARS-CoV-2 ,Health Personnel ,Messenger ,Ce - Letter to the Editor ,COVID-19 ,Italy ,Emergency Medicine ,Internal Medicine ,RNA ,Humans ,RNA, Messenger ,COVID-19 vaccine ,BNT162 Vaccine ,Follow-Up Studies - Abstract
Dear Editor, We read with interest the letter by Serraino and colleagues [1] as they report on our recent study about antibody response to BNT162b2 mRNA COVID-19 vaccine [2]. As a result of the swift development of vaccines for COVID-19 and immunization efforts worldwide, real-world data (RWD) have been collected among several populations and settings confirming vaccination safety, immunogenicity, and efficacy. In so doing, these studies have brought to attention important aspects toward understanding tailored intervention approaches to maximize vaccination campaigns worldwide. Serraino and colleagues [1] report a greater boosting of antibody concentrations when vaccines were administered 2 months or more after SARS-CoV-2 diagnosis, confirming the observations about the role of prior SARS-CoV-2 infection in immune priming [2,3]. It is also in agreement with a recent study of cellular and humoral responses to the first BNT162b2 vaccine dose in previously infected individuals who developed a stronger booster response when the interval between infection and vaccination was extended [4]. Possible explanations for these results have been speculated including a role for memory B cells, whose clonal turnover may modulate the antibody sequence evolution after the first BNT162b2 dose in previously infected subjects [5]. Further research is needed on the functional response of the cellular immune system following SARS-CoV-2 infections and COVID-19 vaccination over different time periods. Presently, there are insufficient data to draw firm conclusions about the optimal timing of a single vaccination dose following infection and a number of factors that limit the comparability of vaccine data across studies, including differences in study design, population and setting. Nonetheless, the practice evidence presented by Serraino and colleagues provides a useful metric to implement the most appropriate vaccination prioritization strategies, particularly in the context of continuous monitoring of vaccine immunogenicity and effectiveness, as well as safety surveillance. Collectively, the work by Serraino and colleagues, together with our findings [2,3], suggest how important it is to use data derived from analysis of real-world evidence to understand how COVID-19 vaccines are helping control the pandemic and to tailor the most appropriate population-level interventions to protect against COVID-19.
- Published
- 2021
9. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months
- Author
-
Ponticelli, Domenico, Antonazzo, Ippazio C., Caci, Grazia, Vitale, Andrea, Della Ragione, Giovanni, Romano, Maria, Borrelli, Mario, Schiavone, Beniamino, Polosa, Riccardo, and Ferrara, Pietro
- Abstract
Emerging evidence is offering significant insights into the effectiveness and safety of the vaccination against the Coronavirus Disease 2019 (COVID-19), but another crucial aspect of the current global vaccination campaign is the time trend of the antibody response to COVID-19 vaccines over a longer period and the resulting duration of the protection offered.1Here, we present data on the dynamics of antibodies that bind SARS-CoV-2 spike (S) protein receptor binding domain (RBD)—the most critical target for SARS-CoV-2-specific antibodies within the S1 sub-unit2—after 6months from the administration with BNT162b2 vaccine. This analysis, built as a longitudinal observational design, is part of the VASCO project (‘Monitoraggio della risposta alVaccinoAnti-SARS-CoV-2/COVID-19 negli operatori sanitari del Pineta Grande Hospital’), which defines an ongoing broad study on the response to BNT162b2 mRNA COVID-19 vaccine in a sample of healthcare workers (HCWs) of the Pineta Grande Hospital (Castel Volturno, Caserta, Italy), investigating effectiveness, immunogenicity and safety of the vaccination. Complete methods of the VASCO project have been presented elsewhere.3 In this survey, HCWs who were administered the two-dose BNT162b2 mRNA vaccine 21days apart between December 2020 and January 2021 were invited to undertake a quantitative serology test for the research of SARS-CoV-2 S-RBD-specific immunoglobulins G (IgG). Seroconversion, defined as the development of any detectable SARS-CoV-2 S-RBD-specific IgG in serum sample, was evaluated through Snibe—Maglumi®SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay (CLIA).4Reactivity was intended as an antibody level equal to or greater than 1.0AU/ml. According to the manufacturer’s recommendations, the Maglumi®SARS-CoV-2 S-RBD IgG CLIA presented sensitivity of 100% (95% confidence interval [CI], 99.9–100%) and specificity of 99.6% (95% CI, 98.7–100%) after the 15th day from symptom onset.4HCWs underwent six longitudinal serological assays every 30days, the first of which was performed within 1 month after completing the vaccination cycle. If a HCW had had a previous infection with SARS-CoV-2 6 months prior to the vaccination or if he/she had contracted the infection after the administration of the first vaccine dose, the cycle was considered complete with a unique dose, as per Italian Ministry of Health guidelines and according to literature findings.5,6CLIA results were expressed as median IgG value and interquartile range (IQR). Differences between medians were assessed through Mann–Whitney U test; multivariate regression analyses were built to investigate the association between the level of the vaccine-elicited antibodies and potential predictors, such as sex, age, previous SARS-CoV-2 infection and post-first dose infection. AP-value of 0.05 was set as significance level. Overall, we analyzed the sera of 162 subjects, being mostly women (58.0%) with a mean age of 42.5years (±11.9 SD). Twenty-eight HCWs had a history of previous SARS-CoV-2 infection. At the first serum sample, the median anti-S-RBD IgG reached 540.0AU/ml (IQR 64.5–1102.0). In the following tests, a progressive decay of antibodies was seen, up to the value of 55.7AU/ml (IQR 26.2–84.7) at the 6-month follow-up (Figure 1). No significant associations were found according to vaccinees’ sex and age. Within 1 month from the vaccination, there was a significant higher S-RBD-reactive antibody response in those subjects with previous SARS-CoV-2 infection (medians: 1534.9 [IQR 1142.0–2000.0] vs. 407.7 [IQR 60.0–846.6];P = 0.001) and the significance remained after adjusting for age and sex (β = 1762.2; 95% CI 1022.9–2501.6;P R2adj = 0.29). Differences in IgG titres between those with previous SARS-CoV-2 infection and those without were no longer significant at the following serological surveys. Three vaccinees tested positive at the RT-PCR assay for qualitative detection of SARS-CoV-2 nucleic acid on nasopharyngeal swabs before the administration of the second vaccine dose; no statistical association was detected between the infection after the first dose and humoral response. No other infections were reported in the follow-up passive surveillance described previously.3
- Published
- 2021
10. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months
- Author
-
Ponticelli, Domenico, primary, Antonazzo, Ippazio C, additional, Caci, Grazia, additional, Vitale, Andrea, additional, Della Ragione, Giovanni, additional, Romano, Maria L, additional, Borrelli, Mario, additional, Schiavone, Beniamino, additional, Polosa, Riccardo, additional, and Ferrara, Pietro, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
- Author
-
Ponticelli, Domenico, primary, Madotto, Fabiana, additional, Conti, Sara, additional, Antonazzo, Ippazio C., additional, Vitale, Andrea, additional, Della Ragione, Giovanni, additional, Romano, Maria L., additional, Borrelli, Mario, additional, Schiavone, Beniamino, additional, Polosa, Riccardo, additional, Ferrara, Pietro, additional, and Mantovani, Lorenzo G., additional
- Published
- 2021
- Full Text
- View/download PDF
12. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months
- Author
-
Ponticelli, D, Antonazzo, I, Caci, G, Vitale, A, Della Ragione, G, Romano, M, Borrelli, M, Schiavone, B, Polosa, R, Ferrara, P, Ponticelli, Domenico, Antonazzo, Ippazio C, Caci, Grazia, Vitale, Andrea, Della Ragione, Giovanni, Romano, Maria L, Borrelli, Mario, Schiavone, Beniamino, Polosa, Riccardo, Ferrara, Pietro, Ponticelli, D, Antonazzo, I, Caci, G, Vitale, A, Della Ragione, G, Romano, M, Borrelli, M, Schiavone, B, Polosa, R, Ferrara, P, Ponticelli, Domenico, Antonazzo, Ippazio C, Caci, Grazia, Vitale, Andrea, Della Ragione, Giovanni, Romano, Maria L, Borrelli, Mario, Schiavone, Beniamino, Polosa, Riccardo, and Ferrara, Pietro
- Published
- 2021
13. Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women
- Author
-
Cortesi, P, Maloberti, A, Micale, M, Pagliarin, F, Antonazzo, I, Mazzaglia, G, Giannattasio, C, Mantovani, L, Cortesi, Paolo Angelo, Maloberti, Alessandro, Micale, Mariangela, Pagliarin, Federica, Antonazzo, Ippazio C., Mazzaglia, Giampiero, Giannattasio, Cristina, Mantovani, Lorenzo G., Cortesi, P, Maloberti, A, Micale, M, Pagliarin, F, Antonazzo, I, Mazzaglia, G, Giannattasio, C, Mantovani, L, Cortesi, Paolo Angelo, Maloberti, Alessandro, Micale, Mariangela, Pagliarin, Federica, Antonazzo, Ippazio C., Mazzaglia, Giampiero, Giannattasio, Cristina, and Mantovani, Lorenzo G.
- Abstract
Background and aims: Ankle brachial index (ABI) is a simple and cheap parameter to assess the presence of atherosclerosis. It could also help correctly reclassify the cardiovascular risk when added to the Framingham risk score (FRS). Recent evidence has demonstrated improvement in prediction performance of ABI when added to FRS, particularly in women. However, no studies have been published yet evaluating the cost-effectiveness of this approach. This study attempts to fill in this gap by assessing the cost-effectiveness of ABI measurements in primary prevention in women. Methods: We developed a Markov model to compare two different strategies for assessing the cardiovascular risk (low, intermediate and high) among women in the general population: 1) FRS strategy, and 2) FRS + ABI strategy; and the relative impact associated with interventions for preventing CV events in intermediate and high-risk categories. Results: In the base-case analysis, FRS + ABI reported an additional cost of € 110 and a gain of 0.0039 QALYs per patient, resulting in an ICER of € 27.986/QALY, when compared to FRS alone. The ICER improved to €1.641/QALY when using a lifetime horizon. The effectiveness of preventive CV disease interventions reported also a significant impact. A 32% reduction of CV events was the minimum value estimated to maintain FRS + ABI as a cost-effective strategy. Conclusions: The addition of ABI to FRS is a cost-effective approach in women classified at low and intermediate risk with FRS only. This new approach gives the possibility to reclassify and allocate them into the appropriate risk group and treatment.
- Published
- 2021
14. Corrigendum: Time-Trends in Air Pollution Impact on Health in Italy, 1990-2019: An Analysis from the Global Burden of Disease Study 2019.
- Author
-
Conti S, Fornari C, Ferrara P, Antonazzo IC, Madotto F, Traini E, Levi M, Cernigliaro A, Armocida B, Bragazzi NL, Cadum E, Carugno M, Crotti G, Deandrea S, Cortesi PA, Guido D, Iavicoli I, Iavicoli S, La Vecchia C, Lauriola P, Michelozzi P, Scondotto S, Stafoggia M, Violante FS, Abbafati C, Albano L, Barone-Adesi F, Biondi A, Bosetti C, Buonsenso D, Carreras G, Castelpietra G, Catapano A, Cattaruzza MS, Corso B, Damiani G, Esposito F, Gallus S, Golinelli D, Hay SI, Isola G, Ledda C, Mondello S, Pedersini P, Pensato U, Perico N, Remuzzi G, Sanmarchi F, Santoro R, Simonetti B, Unim B, Vacante M, Veroux M, Villafañe JH, Monasta L, and Mantovani LG
- Abstract
[This corrects the article DOI: 10.3389/ijph.2023.1605959.]., (Copyright © 2024 Conti, Fornari, Ferrara, Antonazzo, Madotto, Traini, Levi, Cernigliaro, Armocida, Bragazzi, Cadum, Carugno, Crotti, Deandrea, Cortesi, Guido, Iavicoli, Iavicoli, La Vecchia, Lauriola, Michelozzi, Scondotto, Stafoggia, Violante, Abbafati, Albano, Barone-Adesi, Biondi, Bosetti, Buonsenso, Carreras, Castelpietra, Catapano, Cattaruzza, Corso, Damiani, Esposito, Gallus, Golinelli, Hay, Isola, Ledda, Mondello, Pedersini, Pensato, Perico, Remuzzi, Sanmarchi, Santoro, Simonetti, Unim, Vacante, Veroux, Villafañe, Monasta and Mantovani.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.